Differential effects of MAPK pathway inhibitors on migration and invasiveness of BRAFV600E mutant thyroid cancer cells in 2D and 3D culture

Experimental Cell Research

Volumn 338, Issue 2, 2015, Pages 127-135

  Ingeson Carlsson, Camilla ^a   Martinez Monleon, Angela ^a   Nilsson, Mikael ^a  

^a UNIVERSITY OF GOTHENBURG   (Sweden)

Author keywords

3D; BRAF; Cancer; MEK; Migration; PLX4720; Thyroid; U0126

Indexed keywords

1,4 DIAMINO 1,4 BIS(2 AMINOPHENYLTHIO) 2,3 DICYANOBUTADIENE; COLLAGEN GEL; N [3 (5 CHLORO 1H PYRROLO[2,3 B]PYRIDINE 3 CARBONYL) 2,4 DIFLUOROPHENYL]PROPANESULFONAMIDE; 1,3 BUTADIENE DERIVATIVE; ANTINEOPLASTIC AGENT; B RAF KINASE; BRAF PROTEIN, HUMAN; INDOLE DERIVATIVE; MITOGEN ACTIVATED PROTEIN KINASE; NITRILE; PROTEIN KINASE INHIBITOR; SULFONAMIDE;

ANAPLASTIC THYROID CANCER; ANTINEOPLASTIC ACTIVITY; ARTICLE; CELL CULTURE; CELL INVASION; CELL MIGRATION; CELL MUTANT; CELL SURVIVAL; CONTROLLED STUDY; HUMAN; HUMAN CELL; IN VITRO STUDY; PRIORITY JOURNAL; THYROID CANCER CELL LINE; THYROID CARCINOMA; ANTAGONISTS AND INHIBITORS; CARCINOMA; CELL MOTION; CULTURE TECHNIQUE; DRUG EFFECTS; GENETICS; MUTATION; PATHOLOGY; PHOSPHORYLATION; PROCEDURES; SIGNAL TRANSDUCTION; THYROID CARCINOMA, ANAPLASTIC; TUMOR CELL LINE; TUMOR INVASION;

ANTINEOPLASTIC AGENTS; BUTADIENES; CARCINOMA; CELL CULTURE TECHNIQUES; CELL LINE, TUMOR; CELL MOVEMENT; CELL SURVIVAL; HUMANS; INDOLES; MITOGEN-ACTIVATED PROTEIN KINASES; MUTATION; NEOPLASM INVASIVENESS; NITRILES; PHOSPHORYLATION; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS B-RAF; SIGNAL TRANSDUCTION; SULFONAMIDES; THYROID CARCINOMA, ANAPLASTIC;

EID: 84944736067     PISSN: 00144827     EISSN: 10902422     Source Type: Journal    
DOI: 10.1016/j.yexcr.2015.08.003     Document Type: Article

References (38)

1. Baquero P., Sanchez-Hernandez I., Jimenez-Mora E., Orgaz J.L., Jimenez B., Chiloeches A. (V600E)BRAF promotes invasiveness of thyroid cancer cells by decreasing E-cadherin expression through a snail-dependent mechanism. Cancer Lett. 2013, 335:232-241.
2. Begum S., Rosenbaum E., Henrique R., Cohen Y., Sidransky D., Westra W.H. BRAF mutations in anaplastic thyroid carcinoma: implications for tumor origin, diagnosis and treatment. Mod. Pathol. 2004, 17:1359-1363.
3. Bissell M.J., Hines W.C. Why don't we get more cancer? A proposed role of the microenvironment in restraining cancer progression. Nat. Med. 2011, 17:320-329.
4. Bommarito A., Richiusa P., Carissimi E., Pizzolanti G., Rodolico V., Zito G., Criscimanna A., Di Blasi F., Pitrone M., Zerilli M., et al. BRAFV600E mutation, TIMP-1 upregulation, and NF-kappaB activation: closing the loop on the papillary thyroid cancer trilogy. Endocr. Relat. Cancer 2011, 18:669-685.
5. Chen P., Gupta K., Wells A. Cell movement elicited by epidermal growth factor receptor requires kinase and autophosphorylation but is separable from mitogenesis. J. Cell Biol. 1994, 124:547-555.
6. Correia A.L., Bissell M.J. The tumor microenvironment is a dominant force in multidrug resistance. Drug Resist. Updat. 2012, 15:39-49.
7. Dong W., Zhang H., Li J., Guan H., He L., Wang Z., Shan Z., Teng W. Estrogen induces metastatic potential of papillary thyroid cancer cells through estrogen receptor alpha and beta. Int. J. Endocrinol. 2013, 2013:941568.
8. Fenouille N., Tichet M., Dufies M., Pottier A., Mogha A., Soo J.K., Rocchi S., Mallavialle A., Galibert M.D., Khammari A., et al. The epithelial-mesenchymal transition (EMT) regulatory factor SLUG (SNAI2) is a downstream target of SPARC and AKT in promoting melanoma cell invasion. PLoS One 2012, 7:e40378.
9. Flaherty K.T., Infante J.R., Daud A., Gonzalez R., Kefford R.F., Sosman J., Hamid O., Schuchter L., Cebon J., Ibrahim N., et al. Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. N. Engl. J. Med. 2012, 367:1694-1703.
10. Flaherty K.T., Puzanov I., Kim K.B., Ribas A., McArthur G.A., Sosman J.A., O'Dwyer P.J., Lee R.J., Grippo J.F., Nolop K., Chapman P.B. Inhibition of mutated, activated BRAF in metastatic melanoma. N. Engl. J. Med. 2010, 363:809-819.
11. Girotti M.R., Marais R. Deja Vu: EGF receptors drive resistance to BRAF inhibitors. Cancer Discov. 2013, 3:487-490.
12. Hebrant A., Dom G., Dewaele M., Andry G., Tresallet C., Leteurtre E., Dumont J.E., Maenhaut C. mRNA expression in papillary and anaplastic thyroid carcinoma: molecular anatomy of a killing switch. PLoS One 2012, 7:e37807.
13. Husmark J., Heldin N.E., Nilsson M. N-cadherin-mediated adhesion and aberrant catenin expression in anaplastic thyroid-carcinoma cell lines. Int. J. Cancer 1999, 83:692-699.
14. Kimura E.T., Nikiforova M.N., Zhu Z., Knauf J.A., Nikiforov Y.E., Fagin J.A. High prevalence of BRAF mutations in thyroid cancer: genetic evidence for constitutive activation of the RET/PTC-RAS-BRAF signaling pathway in papillary thyroid carcinoma. Cancer Res. 2003, 63:1454-1457.
15. Klein R.M., Higgins P.J. A switch in RND3-RHOA signaling is critical for melanoma cell invasion following mutant-BRAF inhibition. Mol. Cancer 2011, 10:114.
16. Knauf J.A., Sartor M.A., Medvedovic M., Lundsmith E., Ryder M., Salzano M., Nikiforov Y.E., Giordano T.J., Ghossein R.A., Fagin J.A. Progression of BRAF-induced thyroid cancer is associated with epithelial-mesenchymal transition requiring concomitant MAP kinase and TGFbeta signaling. Oncogene 2011, 30:3153-3162.
17. Leboeuf R., Baumgartner J.E., Benezra M., Malaguarnera R., Solit D., Pratilas C.A., Rosen N., Knauf J.A., Fagin J.A. BRAFV600E mutation is associated with preferential sensitivity to mitogen-activated protein kinase kinase inhibition in thyroid cancer cell lines. J. Clin. Endocrinol. Metab. 2008, 93:2194-2201.
18. Lee S.E., Lee J.U., Lee M.H., Ryu M.J., Kim S.J., Kim Y.K., Choi M.J., Kim K.S., Kim J.M., Kim J.W., et al. RAF kinase inhibitor-independent constitutive activation of Yes-associated protein 1 promotes tumor progression in thyroid cancer. Oncogenesis 2013, 2:e55.
19. Liu D., Liu Z., Jiang D., Dackiw A.P., Xing M. Inhibitory effects of the mitogen-activated protein kinase kinase inhibitor CI-1040 on the proliferation and tumor growth of thyroid cancer cells with BRAF or RAS mutations. J. Clin. Endocrinol. Metab. 2007, 92:4686-4695.
20. Montero-Conde C., Ruiz-Llorente S., Dominguez J.M., Knauf J.A., Viale A., Sherman E.J., Ryder M., Ghossein R.A., Rosen N., Fagin J.A. Relief of feedback inhibition of HER3 transcription by RAF and MEK inhibitors attenuates their antitumor effects in BRAF-mutant thyroid carcinomas. Cancer Discov. 2013, 3:520-533.
21. Muranen T., Selfors L.M., Worster D.T., Iwanicki M.P., Song L., Morales F.C., Gao S., Mills G.B., Brugge J.S. Inhibition of PI3K/mTOR leads to adaptive resistance in matrix-attached cancer cells. Cancer Cell 2012, 21:227-239.
22. Nakasone E.S., Askautrud H.A., Kees T., Park J.H., Plaks V., Ewald A.J., Fein M., Rasch M.G., Tan Y.X., Qiu J., et al. Imaging tumor-stroma interactions during chemotherapy reveals contributions of the microenvironment to resistance. Cancer Cell 2012, 21:488-503.
23. Nikiforova M.N., Kimura E.T., Gandhi M., Biddinger P.W., Knauf J.A., Basolo F., Zhu Z., Giannini R., Salvatore G., Fusco A., et al. BRAF mutations in thyroid tumors are restricted to papillary carcinomas and anaplastic or poorly differentiated carcinomas arising from papillary carcinomas. J. Clin. Endocrinol. Metab. 2003, 88:5399-5404.
24. Nilsson M., Dahlman T., Westermark B., Westermark K. Transforming growth factor-beta promotes epidermal growth factor-induced thyroid cell migration and follicle neoformation in collagen gel separable from cell proliferation. Exp. Cell Res. 1995, 220:257-265.
25. Nucera C., Nehs M.A., Nagarkatti S.S., Sadow P.M., Mekel M., Fischer A.H., Lin P.S., Bollag G.E., Lawler J., Hodin R.A., Parangi S. Targeting BRAFV600E with PLX4720 displays potent antimigratory and anti-invasive activity in preclinical models of human thyroid cancer. Oncologist 2011, 16:296-309.
26. Nucera C., Porrello A., Antonello Z.A., Mekel M., Nehs M.A., Giordano T.J., Gerald D., Benjamin L.E., Priolo C., Puxeddu E., et al. B-Raf(V600E) and thrombospondin-1 promote thyroid cancer progression. Proc. Natl. Acad. Sci. USA 2010, 107:10649-10654.
27. Palona I., Namba H., Mitsutake N., Starenki D., Podtcheko A., Sedliarou I., Ohtsuru A., Saenko V., Nagayama Y., Umezawa K., Yamashita S. BRAFV600E promotes invasiveness of thyroid cancer cells through nuclear factor kappaB activation. Endocrinology 2006, 147:5699-5707.
28. Paraiso K.H., Fedorenko I.V., Cantini L.P., Munko A.C., Hall M., Sondak V.K., Messina J.L., Flaherty K.T., Smalley K.S. Recovery of phospho-ERK activity allows melanoma cells to escape from BRAF inhibitor therapy. Br. J. Cancer 2010, 102:1724-1730.
29. Riesco-Eizaguirre G., Rodriguez I., De la Vieja A., Costamagna E., Carrasco N., Nistal M., Santisteban P. The BRAFV600E oncogene induces transforming growth factor beta secretion leading to sodium iodide symporter repression and increased malignancy in thyroid cancer. Cancer Res. 2009, 69:8317-8325.
30. Salerno P., De Falco V., Tamburrino A., Nappi T.C., Vecchio G., Schweppe R.E., Bollag G., Santoro M., Salvatore G. Cytostatic activity of adenosine triphosphate-competitive kinase inhibitors in BRAF mutant thyroid carcinoma cells. J. Clin. Endocrinol. Metab. 2010, 95:450-455.
31. Schweppe R.E., Kerege A.A., Sharma V., Poczobutt J.M., Gutierrez-Hartmann A., Grzywa R.L., Haugen B.R. Distinct genetic alterations in the mitogen-activated protein kinase pathway dictate sensitivity of thyroid cancer cells to mitogen-activated protein kinase kinase 1/2 inhibition. Thyroid 2009, 19:825-835.
32. Straussman R., Morikawa T., Shee K., Barzily-Rokni M., Qian Z.R., Du J., Davis A., Mongare M.M., Gould J., Frederick D.T., et al. Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion. Nature 2012, 487:500-504.
33. van Staveren W.C., Solis D.W., Delys L., Duprez L., Andry G., Franc B., Thomas G., Libert F., Dumont J.E., Detours V., Maenhaut C. Human thyroid tumor cell lines derived from different tumor types present a common dedifferentiated phenotype. Cancer Res. 2007, 67:8113-8120.
34. van Staveren W.C., Solis D.Y., Hebrant A., Detours V., Dumont J.E., Maenhaut C. Human cancer cell lines: experimental models for cancer cells in situ? For cancer stem cells?. Biochim. Biophys. Acta 2009, 1795:92-103.
35. Vasko V., Espinosa A.V., Scouten W., He H., Auer H., Liyanarachchi S., Larin A., Savchenko V., Francis G.L., de la Chapelle A., et al. Gene expression and functional evidence of epithelial-to-mesenchymal transition in papillary thyroid carcinoma invasion. Proc. Natl. Acad. Sci. USA 2007, 104:2803-2808.
36. Vultur A., Villanueva J., Krepler C., Rajan G., Chen Q., Xiao M., Li L., Gimotty P.A., Wilson M., Hayden J., Keeney F., Nathanson K.L., Herlyn M. MEK inhibition affects STAT3 signaling and invasion in human melanoma cell lines. Oncogene 2014, 33(14). 1850-61. 10.1038/onc.2013.131. Epub 2013 Apr 29.
37. Xing M., Alzahrani A.S., Carson K.A., Viola D., Elisei R., Bendlova B., Yip L., Mian C., Vianello F., Tuttle R.M., et al. Association between BRAF V600E mutation and mortality in patients with papillary thyroid cancer. JAMA 2013, 309:1493-1501.
38. Xing M., Westra W.H., Tufano R.P., Cohen Y., Rosenbaum E., Rhoden K.J., Carson K.A., Vasko V., Larin A., Tallini G., et al. BRAF mutation predicts a poorer clinical prognosis for papillary thyroid cancer. J. Clin. Endocrinol. Metab. 2005, 90:6373-6379.